Roche strengthens infectious drugs pipeline

As reported by InPharm, pharmaceutical giant, Roche, has acquired Anadys, a company that specialises in the development of hepatitis C treatments for $230 million.

The acquisition highlights a strategic move by Roche to strengthen it’s infectious drugs pipeline and move outside it’s oncology franchise. Speaking of the acquisition, Jean-Jacques Garaud, Roche’s global head of their research and early development department stated, “This acquisition augments our already strong HCV portfolio.

“Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon.

Anadys’ most advanced infectious drug setrobuvir is currently in Phase II studies with Roche’s inferferon drugs Pegasys and Copegus.

Are you looking for a new role in drug development? Click here to search our current jobs online now.

Posted in: Featured Jobs, News
CK Logo in place of featured image